THE COMBINATION OF AQ4N AND RADIOTHERAPY AS A TREATMENT IN HYPOXIA IN SOLID TUMORS
Hypoxia literally means “deficiency in oxygen.” Hypoxia in solid tumors is primarily is a pathophysiologic consequence of structurally and functionally disturbed microcirculation and the deterioration of diffusion conditions.”
Hypoxia shows to be strongly associated with the propagation of tumor, malignancy progression, and resistance to therapy. Thus, Hypoxia becomes one of the major concerns of tumor physiology and cancer treatments. (Cat, 2007)
AQ4N is a novel bioreductive prodrug under clinical investigation. Preclinical evidence shows that AQ4N deeply penetrates the tumor cells and undergo selective activation to form a potent topoisomerase II inhibitor, in Hypoxic regions of solid tumors.
Radiotherapy on the other hand, is one of the most common treatments to malignant cancers. It consists of ionizing radiation that is use to control the spread of malignant cells. (Radiotherapy, 2008)
There have been separate studies of the effectiveness of AQ4N to hypoxia as well as radiotherapy to hypoxia. However, there have been no studies yet using both AQ4N and radiotherapy as a treatment to Hypoxia. This study would like to make an extended research with both AQ4N and Radiotherapy as variables in the study. This study will research on the effectiveness of both AQ4N and Radiotherapy when used as a treatment to hypoxia at the same time.
This study will use medical books and related experiments to further strengthen the findings of the study.
This study will consist of experiments to hypoxia patients. This study will be be beneficial to both patients and cancer specialists.
Credit:ivythesis.typepad.com
0 comments:
Post a Comment